Aytu BioPharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aytu BioPharma, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Jun 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 64% of Healthcare companies in United States.
Cash Locked Ratio
$32For every $100 of sales, $32 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $26 tied up three years earlier.
More money tied up than 70% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 46%
Sales fell 46% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-46% / -23%In 3 years sales changed by -46% while total assets changed by -23%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.4×Debt due within a year is covered 0.4 times by its yearly operating cash.
Higher than 70% of Healthcare companies in United States.
Cash Cushion Ratio
+43%Cash, after subtracting all debt, equals 43% of its market value (net cash).
Higher than 75% of Healthcare companies in United States.
Tangible Assets Ratio
61%Of every $100 the company owns, $61 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 69% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 78% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Aytu BioPharma, Inc. made a loss over the last year. Aytu BioPharma, Inc. owes $0.66 for every $1 it owns. Aytu BioPharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Jun 2026.
P/E ratio
LossAytu BioPharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.61The share price is 0.61 times Aytu BioPharma, Inc.'s book value per share, lower than 88% of Healthcare companies in United States.
Market cap
$22 MThe total market value of all of Aytu BioPharma, Inc.'s shares at today's price (share price × number of shares), smaller than 81% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$35 MWhat Aytu BioPharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.25Net worth divided by the number of shares. The share price of $1.98 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-52.5%Aytu BioPharma, Inc. lost 52.5% of its shareholders' money over the last year, lower than 52% of Healthcare companies in United States.
Owes vs Owns
0.66×Aytu BioPharma, Inc. owes $0.66 for every $1 it owns (moderate), higher than 70% of Healthcare companies in United States.
Dividend yield
NoneAytu BioPharma, Inc. does not currently pay a dividend.
Revenue growth
-13%Revenue fell 13% in the year to Jun 2026, and shrank 19% a year on average over 3 years.
Profit growth
LossAytu BioPharma, Inc. made a loss in each of the last two years.
Profit margin
-24.8%Aytu BioPharma, Inc. lost $25 for every $100 of revenue.
Interest cover
Not coveredAytu BioPharma, Inc.'s operating profit did not cover its interest costs in the year to Jun 2026.
Cash vs debt
Net cashAytu BioPharma, Inc. held $9 M more cash than debt (net cash) at Jun 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aytu BioPharma, Inc.: $22 M ÷ $35 M (30 Jun 2026) = 0.6.
What is Aytu BioPharma, Inc.'s return on equity?
Aytu BioPharma, Inc. lost 52.5% of its shareholders' money over the last year, lower than 52% of Healthcare companies in United States.
How much does Aytu BioPharma, Inc. owe compared with what it owns?
Aytu BioPharma, Inc. owes $0.66 for every $1 it owns (moderate), higher than 70% of Healthcare companies in United States.
Does Aytu BioPharma, Inc. pay a dividend?
No. Aytu BioPharma, Inc. does not currently pay a dividend.
Is Aytu BioPharma, Inc.'s revenue growing?
Revenue fell 13% in the year to Jun 2026, and shrank 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.